ACCENDRA HEALTH INC/VA/ — fact timeline

Edward A. Pesicka departed as President, Chief Executive Officer & Director at ACCENDRA HEALTH INC/VA/.

“On August 10, 2026, Accendra Health, Inc. (the “Company”) announced that Edward A. Pesicka, President, Chief Executive Officer & Director of the Company, notified the board of directors (the “Board”) of the Company of his intention to retire and step down from the Board by the end of 2026, or such earlier time as a successor is appointed.”

ACCENDRA HEALTH INC/VA/ amended senior notes of $4,257,000 aggregate principal amount of 2030 Notes with the trustee of the Existing Notes Indentures at 6.625% maturing 2030.

“On June 9, 2026 the Company entered into supplemental indentures to the Existing Notes Indentures (the “Existing Notes Supplemental Indentures”) to effectuate the Amendments.”

ACCENDRA HEALTH INC/VA/ amended senior notes of $363,000 aggregate principal amount of 2029 Notes with the trustee of the Existing Notes Indentures at 4.500% maturing 2029.

“On June 9, 2026 the Company entered into supplemental indentures to the Existing Notes Indentures (the “Existing Notes Supplemental Indentures”) to effectuate the Amendments.”

ACCENDRA HEALTH INC/VA/ incurred senior notes of $698.0 million aggregate principal amount of Second Lien Notes with Regions Bank (as trustee) at 9.750% per year maturing June 15, 2033.

“On June 15, 2026 (the “Early Settlement Date”), the Company issued (i) $213.0 million in aggregate principal amount of First Lien Notes and (ii) $698.0 million in aggregate principal amount of Second Lien Notes, in exchange for the validly tendered and accepted Early Tendered Notes, and issued $326.25 million in aggregate principal amount of First Lien Notes in the new money issuance, for a total of $539.25 million First Lien Notes.”

ACCENDRA HEALTH INC/VA/ incurred senior notes of $539.25 million aggregate principal amount of First Lien Notes with Regions Bank (as trustee) at 9.000% per year maturing June 15, 2032.

“On June 15, 2026 (the “Early Settlement Date”), the Company issued (i) $213.0 million in aggregate principal amount of First Lien Notes and (ii) $698.0 million in aggregate principal amount of Second Lien Notes, in exchange for the validly tendered and accepted Early Tendered Notes, and issued $326.25 million in aggregate principal amount of First Lien Notes in the new money issuance, for a total of $539.25 million First Lien Notes.”

ACCENDRA HEALTH INC/VA/ entered into New Notes Indentures (First Lien Indenture and Second Lien Indenture) with Regions Bank valued at First Lien Notes bear interest at 9.000% per year; Second Lien Notes bear interest at 9.750% per yea (effective 2026-06-15).

“The First Lien Notes issued as part of the new money issuance and delivered in exchange for the 2029 Notes tendered prior to the Early Exchange Time were issued pursuant to the Indenture, dated June 15, 2026 (the “First Lien Indenture”), by and among the Company, the guarantors named therein and Regions Bank, as trustee (in such capacity, the “First Lien Trustee”) and as collateral agent (in such capacity, the “First Lien Collateral Agent”) and the Second Lien Notes delivered in exchange for the Early Tendered Notes were, and any Second Lien Notes delivered in exchange for any remaining Existing Notes that are validly tendered in the Exchange Offers following the Early Exchange Time and at or prior to the Expiration Time will be, issued pursuant to the Indenture, dated June 15, 2026 (the “Second Lien Indenture” and, together with the First Lien Indenture, the “New Indentures”), by and among the Company, the guarantors named therein and Regions Bank, as trustee (in such capacity, the “S”

ACCENDRA HEALTH INC/VA/ shareholders approved Approval of the Accendra Health, Inc. Amended and Restated 2023 Omnibus Incentive Plan at the 2026-05-14 meeting.

“Approval of the Accendra Health, Inc. Amended and Restated 2023 Omnibus Incentive Plan as follows: ​ Votes Votes For Votes Against Abstentions Broker Non- Votes 50,645,557 1,573,141 151,765 9,763,670”

ACCENDRA HEALTH INC/VA/ shareholders approved Non-binding advisory vote to approve the compensation of our named executive officers at the 2026-05-14 meeting.

“Non-binding advisory vote to approve the compensation of our named executive officers as follows: ​ Votes Votes For Votes Against Abstentions Broker Non- Votes 48,137,834 4,098,288 134,341 9,763,670”

ACCENDRA HEALTH INC/VA/ shareholders approved Ratification of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-05-14 meeting.

“Ratification of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 as follows: ​ Votes Votes For Votes Against Abstentions Broker Non- Votes 61,255,312 693,111 185,710 -”

ACCENDRA HEALTH INC/VA/ shareholders approved Election of six directors, each for a one-year term at the 2026-05-14 meeting.

“Election of six directors, each for a one-year term, as follows: ​ Votes ​ Director Votes For Votes Against Abstentions Broker Non- Votes Mark A. Beck 50,962,576 1,294,183 113,704 9,763,670 Gwendolyn M. Bingham 51,120,827 1,136,584 113,052 9,763,670 Kenneth Gardner-Smith 50,944,000 1,312,205 114,258 9,763,670 Stephen W. Klemash 51,165,959 1,090,992 113,512 9,763,670 Teresa L. Kline 51,189,677 1,068,135 112,651 9,763,670 Edward A. Pesicka 48,760,777 3,497,266 112,420 9,763,670”

ACCENDRA HEALTH INC/VA/ entered into Commitment and Consent Letter with certain institutions that are holders of the 4.500% Senior Notes due 2029 and 6.625% Senior Notes due 2030, lenders under the Term Loan Credit Agreement, and lenders under the Existing Revolving Credit Facility Agreement (effective 2026-05-11).

“On May 11, 2026, Accendra Health, Inc. (the “ Company ”) entered into a Commitment and Consent Letter (the “ Commitment Letter ”) with certain institutions that are (a)(i) holders of the Company’s 4.500% Senior Notes due 2029 (the “ 2029 Notes ”) and 6.625% Senior Notes due 2030 (the “ 2030 Notes ” and, together with the 2029 Notes, the “ Existing Notes ”), collectively holding approximately all of the outstanding principal amount of the 2029 Notes and approximately 83% of the outstanding principal amount of the 2030 Notes as of May 11, 2026 and (ii) lenders under the Company’s existing Term Loan Credit Agreement (as defined below) (collectively, the “ Commitment and Consenting Parties ” and each, a “ Commitment and Consenting Party ”), (b) certain lenders under the Company’s existing Term Loan Credit Agreement consenting solely with respect to the Term B-1 Term Loan Consent (as defined below) (the “ Term B-1 Term Loan Consenting Parties ”) and (c) all lenders under the Company’s Exist”

ACCENDRA HEALTH INC/VA/ reported the first quarter ended March 31, 2026 results: revenue $ 627.8, net income $ (6.5), EPS $ (0.08).

“Commission this morning. ​ Details on First Quarter 2026 Results ​ ​ First Quarter Results (1) ​ ($ in millions, except per share data) ​ ​ ​ 1Q26 ​ ​ ​ 1Q25 Net Revenue ​ $ 627.8 ​ $ 673.9 ​ ​ ​ ​ ​ ​ ​ Loss from continuing operations, net of tax, GAAP ​ $ (6.5) ​ $ (3.8) Adj. net (loss) income from continuing operations, Non-GAAP ​ $ (3.1) ​ $ 23.2 ​ ​ ​”

ACCENDRA HEALTH INC/VA/: Filed articles of amendment to certificate of incorporation to change corporate name (effective 2025-12-24).

“On December 24, 2025, the Company filed articles of amendment to its certificate of incorporation (the “ Articles of Amendment ”) and amended its bylaws (the “ Second Amended and Restated Bylaws ”) to change the corporate name set forth therein from “Owens & Minor, Inc.” to “Accendra Health, Inc.””

ACCENDRA HEALTH INC/VA/: Amended bylaws to change corporate name from Owens & Minor, Inc. to Accendra Health, Inc (effective 2025-12-24).

“On December 24, 2025, the Company filed articles of amendment to its certificate of incorporation (the “ Articles of Amendment ”) and amended its bylaws (the “ Second Amended and Restated Bylaws ”) to change the corporate name set forth therein from “Owens & Minor, Inc.” to “Accendra Health, Inc.””

ACCENDRA HEALTH INC/VA/ amended Amended & Restated Receivables Purchase Agreement with PNC Bank, National Association, PNC Capital Markets LLC valued at $150 million.

“On the Closing Date, O&M Funding LLC (“ O&M Funding ”), as Seller, and Byram Healthcare Centers, Inc. (“ Byram ”), as initial Servicer, each a wholly-owned subsidiary of the Company, entered into an Amended & Restated Receivables Purchase Agreement (the “ Amended & Restated Receivables Purchase Agreement ”) with persons from time to time party thereto, as Purchasers, PNC Bank, National Association (“ PNC ”), as Administrative Agent, and PNC Capital Markets LLC, as Structuring Agent, pursuant to which accounts receivable with an aggregate outstanding amount not to exceed $150 million are sold”

ACCENDRA HEALTH INC/VA/ incurred debt of aggregate outstanding amount not to exceed $150 million with PNC Bank, National Association maturing Scheduled Termination Date of October 18, 2027.

“On the Closing Date, O&M Funding LLC (“ O&M Funding ”), as Seller, and Byram Healthcare Centers, Inc. (“ Byram ”), as initial Servicer, each a wholly-owned subsidiary of the Company, entered into an Amended & Restated Receivables Purchase Agreement (the “ Amended & Restated Receivables Purchase Agreement ”) with persons from time to time party thereto, as Purchasers, PNC Bank, National Association (“ PNC ”), as Administrative Agent, and PNC Capital Markets LLC, as Structuring Agent, pursuant to which accounts receivable with an aggregate outstanding amount not to exceed $150 million are sold, on a limited-recourse basis, to the Purchasers in exchange for cash (the “ Receivables Sale Program ”).”

ACCENDRA HEALTH INC/VA/ completed a disposition involving Dominion Healthcare Acquisition Corporation and Dominion Healthcare Holdings, L.P. for $375 million in cash (closed 2025-12-31).

“effect to the completion of certain reorganization transactions, comprises the “ Products & Healthcare Services ” or “ P&HS ” business of the Company), for an aggregate of $375 million in cash, subject to certain adjustments for cash, indebtedness, net working capital and transaction expenses (the “ Sale ”) and (ii) contributed, assigned, transferred and”

ACCENDRA HEALTH INC/VA/ faced acceleration on senior notes of $1,000,000,000 aggregate principal amount with Regions Bank at 10.000% maturing due 2030.

“of April 4, 2025, by and among the Company, the guarantors named therein and Regions Bank, as trustee and as collateral agent (the “Indenture”), under which the Company issued $1,000,000,000 aggregate principal amount of 10.000% Senior Secured Notes due 2030 (the “Notes”), the Company is required to redeem such Notes. On June 5, 2025, the Company issued a notice of”

ACCENDRA HEALTH INC/VA/ incurred senior notes of $1,000,000,000 aggregate principal amount with Regions Bank at 10.000% per year maturing due 2030.

“On April 4, 2025, Owens & Minor, Inc. (the “Company”), completed its previously announced sale of $1,000,000,000 aggregate principal amount of the Company’s 10.000% senior secured notes due 2030 (the “New Notes”) in a private offering (the “Offering”) that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”).”

Jonathan A. Leon was appointed as Executive Vice President, Chief Financial Officer at ACCENDRA HEALTH INC/VA/.

“On September 23, 2024, Owens & Minor, Inc. (the “Company”) announced that Jonathan A. Leon, age 58, has been appointed Executive Vice President, Chief Financial Officer of the Company, effective September 23, 2024.”

Jonathan A. Leon was appointed as Interim Chief Financial Officer at ACCENDRA HEALTH INC/VA/.

“Jonathan A. Leon, the Company’s Senior Vice President, Corporate Treasurer, has been appointed as interim Chief Financial Officer effective June 21, 2024.”

Alexander J. Bruni resigned as Executive Vice President & Chief Financial Officer at ACCENDRA HEALTH INC/VA/.

“Alexander J. Bruni, the Company’s Executive Vice President & Chief Financial Officer, has, at the request of the Company, resigned from his position as an officer of the Company, effective June 21, 2024.”

Jennifer Stone was named as Executive Vice President & Chief Human Resources Officer at ACCENDRA HEALTH INC/VA/.

“On May 24, 2024, Owens & Minor, Inc. (the Company) named Jennifer Stone (53) Executive Vice President & Chief Human Resources Officer of the Company effective June 3, 2024.”

ACCENDRA HEALTH INC/VA/ shareholders approved Advisory vote to approve the compensation of our named executive officers at the 2024-05-09 meeting.

“2023 Omnibus Incentive Plan, as follows: ​ Votes ​ Votes For Votes Against Abstentions Broker Non- Votes 64,181,423 3,371,256 52,817 3,113,777 ​ (4) Advisory vote to approve the compensation of our named executive officers as follows: ​ Votes ​ Votes For Votes Against Abstentions Broker Non- Votes 66,163,767 1,381,531 60,198 3,113,777 ​ ​ ​ ​ ​ SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.”

ACCENDRA HEALTH INC/VA/ shareholders approved Approval of Amendment No. 1 to the Owens & Minor, Inc. 2023 Omnibus Incentive Plan at the 2024-05-09 meeting.

“(3) Approval of Amendment No. 1 to the Owens & Minor, Inc. 2023 Omnibus Incentive Plan”

ACCENDRA HEALTH INC/VA/ shareholders approved Ratification of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 at the 2024-05-09 meeting.

“(2) Ratification of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024”

ACCENDRA HEALTH INC/VA/ shareholders approved Election of nine directors, each for a one-year term at the 2024-05-09 meeting.

“​ (1) Election of nine directors, each for a one-year term, as follows: ​ Director Votes For Votes Against Abstentions Broker Non- Votes Mark A.”

Snehashish Sarkar was named as Executive Vice President & Chief Information Officer at ACCENDRA HEALTH INC/VA/.

“On May 9, 2024 Owens & Minor, Inc. (the Company) named Snehashish Sarkar (49) Executive Vice President & Chief Information Officer of the Company.”

ACCENDRA HEALTH INC/VA/ reported the first quarter ended March 31, 2024 results: revenue $2.6 billion, net income $(0.29) per share.

“VA – May 3, 2024 – Owens & Minor, Inc. (NYSE: OMI) today reported financial results for the first quarter ended March 31, 2024. ​ Key Highlights: ● Consolidated revenue of $2.6 billion in the first quarter, representing year-over-year growth of 4% ● GAAP operating margin was flat while adjusted operating margin expanded by 31 basis points versus prior year ●”

Dan J. Starck retired as Executive Vice President, Business Excellence at ACCENDRA HEALTH INC/VA/.

“On April 16, 2024, Dan J. Starck, Executive Vice President, Business Excellence of Owens & Minor, Inc. (the “Company”), informed the Company that he was retiring from his position at the Company, effective May 17, 2024.”

ACCENDRA HEALTH INC/VA/ reported the fourth quarter and year ended December 31, 2023 results: revenue $10.3 billion, net income Net loss per common share of $(0.54) and adjusted net income per common share of $1.36.

“& Minor, Inc. (NYSE: OMI) today reported financial results for the fourth quarter and year ended December 31, 2023. ​ Full Year 2023 Key Highlights: ● Consolidated revenue of $10.3 billion ● Delivered $741 million of operating cash flow ● Reduced total debt by $403 million and reduced net debt by $577 million ● Net loss per common share of $(0.54) and adjusted net”

Tammy L. Gomez resigned as Executive Vice President and Chief Human Resources Officer at ACCENDRA HEALTH INC/VA/.

“On December 11, 2023, Tammy L. Gomez, Executive Vice President and Chief Human Resources Officer of Owens & Minor, Inc. (the “Company”), informed the Company that she was resigning from her position at the Company, effective December 15, 2023, to accept a position with a large industrial conglomerate.”

ACCENDRA HEALTH INC/VA/ reported nine months ended September 30, 2023 results: revenue $7,678.

“YTD YTD ($ in millions, except per share data) 3Q23 3Q22 2023 2022 Revenue $2,592 $2,497 $7,678 $7,404 Operating income, GAAP $23.8 $60.2 $44.5 $196.4”

ACCENDRA HEALTH INC/VA/ reported third quarter ended September 30, 2023 results: revenue $2.59 billion, net income Net loss per common share of $(0.08), EPS $(0.08).

“2023 – Owens & Minor, Inc. (NYSE: OMI) today reported financial results for the third quarter ended September 30, 2023. Third Quarter Key Highlights: • Consolidated revenue of $2.59 billion • Net loss per common share of $(0.08) and adjusted net income per common share of $0.44 • $188 million in total debt pay down and $117 million reduction in net debt “Our”

ACCENDRA HEALTH INC/VA/ reported six months ended June 30, 2023 results: revenue $5,086, net income $(52.7), EPS $(0.70).

“Financial Summary (1) YTD YTD ($ in millions, except per share data) 2Q23 2Q22 2023 2022 Revenue $2,563 $2,500 $5,086 $4,907 Operating income, GAAP $10.8 $75.1 $20.6 $136.1 Adj. Operating Income, Non-GAAP $62.0 $113.6 $109.7 $218.5 Net (loss) income, GAAP $(28.2) $28.6 $(52.7) $67.9 Adj. Net Income, Non-GAAP $14.2 $58.3 $17.8 $131.0 Adj. EBITDA, Non-GAAP $112.8 $163.4 $221.5 $285.9 Net (loss) income per common share, GAAP $(0.37) $0.37 $(0.70) $0.89 Adj. Net Income per share, Non-GAAP $0.18 $0.76 $0.23 $1.72”

ACCENDRA HEALTH INC/VA/ reported second quarter ended June 30, 2023 results: revenue $2.56 billion, net income $(0.37) per common share, EPS $(0.37) per common share.

“Owens & Minor, Inc. (NYSE: OMI) today reported financial results for the second quarter ended June 30, 2023. Second Quarter Key Highlights: • Consolidated revenue of $2.56 billion • Net loss per common share of $(0.37) and adjusted net income per common share of $0.18”

ACCENDRA HEALTH INC/VA/ shareholders approved Advisory vote to approve the compensation of our named executive officers at the 2023-05-11 meeting.

“Item 5.07 Submission of Matters to a Vote of Security Holders. At the Company’s Annual Meeting on May 11, 2023, the matters described below were voted upon and approved as indicated. There were 76,192,213 shares of common stock entitled to vote at the meeting and 72,760,190 shares were voted in person or by proxy (approximately 95.50% of shares entitled to vote). 1. Election of nine directors, each for a one-year term, as follows: Director Votes For Votes Against Abstentions Broker Non-Votes Mark A. Beck 68,479,605 500,210 26,978 3,753,397 Gwendolyn M. Bingham 67,353,125 1,626,619 27,049 3,753,397 Kenneth Gardner-Smith 68,286,327 685,584 34,882 3,753,397 Robert J. Henkel 67,861,731 1,110,504 34,558 3,753,397 Rita F. Johnson-Mills 68,205,506 759,471 41,816 3,753,397 Stephen W. Klemash 68,396,191 582,730 27,872 3,753,397 Teresa L. Kline 68,399,390 580,108 27,295 3,753,397 Edward A. Pesicka 68,574,396 401,989 30,408 3,753,397 Carissa L. Rollins 68,531,340 449,083 26,370 3,753,397 2. Appro”

ACCENDRA HEALTH INC/VA/ shareholders approved Ratification of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-11 meeting.

“Item 5.07 Submission of Matters to a Vote of Security Holders. At the Company’s Annual Meeting on May 11, 2023, the matters described below were voted upon and approved as indicated. There were 76,192,213 shares of common stock entitled to vote at the meeting and 72,760,190 shares were voted in person or by proxy (approximately 95.50% of shares entitled to vote). 1. Election of nine directors, each for a one-year term, as follows: Director Votes For Votes Against Abstentions Broker Non-Votes Mark A. Beck 68,479,605 500,210 26,978 3,753,397 Gwendolyn M. Bingham 67,353,125 1,626,619 27,049 3,753,397 Kenneth Gardner-Smith 68,286,327 685,584 34,882 3,753,397 Robert J. Henkel 67,861,731 1,110,504 34,558 3,753,397 Rita F. Johnson-Mills 68,205,506 759,471 41,816 3,753,397 Stephen W. Klemash 68,396,191 582,730 27,872 3,753,397 Teresa L. Kline 68,399,390 580,108 27,295 3,753,397 Edward A. Pesicka 68,574,396 401,989 30,408 3,753,397 Carissa L. Rollins 68,531,340 449,083 26,370 3,753,397 2. Appro”

ACCENDRA HEALTH INC/VA/ shareholders approved Approval of the Owens & Minor, Inc. 2023 Omnibus Incentive Plan at the 2023-05-11 meeting.

“Item 5.07 Submission of Matters to a Vote of Security Holders. At the Company’s Annual Meeting on May 11, 2023, the matters described below were voted upon and approved as indicated. There were 76,192,213 shares of common stock entitled to vote at the meeting and 72,760,190 shares were voted in person or by proxy (approximately 95.50% of shares entitled to vote). 1. Election of nine directors, each for a one-year term, as follows: Director Votes For Votes Against Abstentions Broker Non-Votes Mark A. Beck 68,479,605 500,210 26,978 3,753,397 Gwendolyn M. Bingham 67,353,125 1,626,619 27,049 3,753,397 Kenneth Gardner-Smith 68,286,327 685,584 34,882 3,753,397 Robert J. Henkel 67,861,731 1,110,504 34,558 3,753,397 Rita F. Johnson-Mills 68,205,506 759,471 41,816 3,753,397 Stephen W. Klemash 68,396,191 582,730 27,872 3,753,397 Teresa L. Kline 68,399,390 580,108 27,295 3,753,397 Edward A. Pesicka 68,574,396 401,989 30,408 3,753,397 Carissa L. Rollins 68,531,340 449,083 26,370 3,753,397 2. Appro”

ACCENDRA HEALTH INC/VA/ shareholders approved Election of nine directors, each for a one-year term at the 2023-05-11 meeting.

“Item 5.07 Submission of Matters to a Vote of Security Holders. At the Company’s Annual Meeting on May 11, 2023, the matters described below were voted upon and approved as indicated. There were 76,192,213 shares of common stock entitled to vote at the meeting and 72,760,190 shares were voted in person or by proxy (approximately 95.50% of shares entitled to vote). 1. Election of nine directors, each for a one-year term, as follows: Director Votes For Votes Against Abstentions Broker Non-Votes Mark A. Beck 68,479,605 500,210 26,978 3,753,397 Gwendolyn M. Bingham 67,353,125 1,626,619 27,049 3,753,397 Kenneth Gardner-Smith 68,286,327 685,584 34,882 3,753,397 Robert J. Henkel 67,861,731 1,110,504 34,558 3,753,397 Rita F. Johnson-Mills 68,205,506 759,471 41,816 3,753,397 Stephen W. Klemash 68,396,191 582,730 27,872 3,753,397 Teresa L. Kline 68,399,390 580,108 27,295 3,753,397 Edward A. Pesicka 68,574,396 401,989 30,408 3,753,397 Carissa L. Rollins 68,531,340 449,083 26,370 3,753,397 2. Appro”

ACCENDRA HEALTH INC/VA/ reported the first quarter ended March 31, 2023 results: revenue $2,523, net income $(24.4), EPS $(0.32). Guidance raised.

“Financial Summary (1) ($ in millions, except per share data) 1Q23 1Q22 Revenue $2,523 $2,407 Operating income, GAAP $9.8 $61.1 Adj. Operating Income, Non-GAAP $47.7 $104.9 Net (loss) income, GAAP $(24.4) $39.3 Adj. Net Income, Non-GAAP $3.6 $72.8 Adj. EBITDA, Non-GAAP $108.7 $122.6 Net (loss) income per common share, GAAP $(0.32) $0.52 Adj. Net Income per share, Non-GAAP $0.05 $0.96”

Heath H. Galloway was appointed as Executive Vice President, General Counsel and Corporate Secretary at ACCENDRA HEALTH INC/VA/.

“The Company has named Heath H. Galloway (46) as Executive Vice President, General Counsel and Corporate Secretary effective upon Mr. Pace’s departure.”

Nicholas J. Pace resigned as Executive Vice President, General Counsel and Corporate Secretary at ACCENDRA HEALTH INC/VA/.

“On April 13, 2023, Nicholas J. Pace, Executive Vice President, General Counsel and Corporate Secretary of Owens & Minor, Inc. (the “Company”), informed the Company that he was resigning from his position at the Company, effective May 17, 2023, to accept a role as executive vice president & general counsel with a privately-held revenue cycle management company.”

ACCENDRA HEALTH INC/VA/ reported the year ended December 31, 2022 results: revenue $9,955, net income $22.4, EPS $0.29.

“Financial Summary (1) FYE FYE ($ in millions, except per share data) 4Q22 4Q21 2022 2021 Revenue $2,551 $2,467 $9,955 $9,785 Operating (loss) income, GAAP $(53.5) $62.0 $142.9 $368.5 Adj. Operating Income, Non-GAAP $67.2 $84.9 $369.1 $442.4 Net (loss) income, GAAP $(58.0) $42.0 $22.4 $221.6 Adj. Net Income, Non-GAAP $21.7 $61.2 $184.2 $309.3 Adj. EBITDA, Non-GAAP $116.7 $97.4 $517.8 $492.3 Net (loss) income per common share, GAAP $(0.77) $0.55 $0.29 $2.94 Adj. Net Income per share, Non-GAAP (2) $0.28 $0.81 $2.42 $4.10”

ACCENDRA HEALTH INC/VA/ reported the third quarter ended September 30, 2022 results: revenue $2,497, net income $12.5, EPS $0.16.

“as our execution and market conditions improve,” Pesicka concluded. Financial Summary (1) ($ in millions, except per share data) 3Q22 3Q21 YTD 2022 YTD 2021 Revenue $2,497 $2,502 $7,404 $7,318 Operating income, GAAP $60.2 $62.9 $196.4 $306.5 Adj. Operating Income, Non-GAAP $83.4 $79.3 $301.9 $357.5 Net income, GAAP $12.5 $44.1 $80.4 $179.6 Adj. Net”

Alexander J. Bruni was appointed as Executive Vice President & Chief Financial Officer at ACCENDRA HEALTH INC/VA/.

“Alexander J. Bruni, age 46, has been appointed Executive Vice President & Chief Financial Officer of the Company replacing Mr. Long effective October 12, 2022.”

Andrew G. Long was appointed as Executive Vice President, Chief Executive Officer of Products & Healthcare Services Segment at ACCENDRA HEALTH INC/VA/.

“Andrew G. Long, the Company’s Executive Vice President & Chief Financial Officer has been appointed as Executive Vice President, Chief Executive Officer of the Company’s Products & Healthcare Services segment, effective October 12, 2022.”

Mark F. McGettrick resigned as Director at ACCENDRA HEALTH INC/VA/.

“Additionally, Mark F. McGettrick notified the Company that he will resign from the Company’s Board, effective July 12, 2022.”

Carissa Rollins was elected as Director at ACCENDRA HEALTH INC/VA/.

“Effective July 12, 2022, the Board of Directors (the “Board”) of Owens & Minor, Inc. (the “Company”) elected Carissa Rollins, to serve on the Board of the Company and appointed Ms. Rollins to serve on the Audit and Our People & Culture Committees of the Board.”

Teresa L. Kline was elected as Director at ACCENDRA HEALTH INC/VA/.

“Effective June 1, 2022, the Board of Directors (the “Board”) of Owens & Minor, Inc. (the “Company”) elected two directors, Rita F. Johnson-Mills and Teresa L. Kline (the “Elected Directors”), to serve on the Board of the Company.”